active surveillance

Active Surveillance Superior to Surgery for Quality of Life in Low-Risk Thyroid Cancer: Insights from a Global Meta-Analysis

By MedXY 12/28/2025

A comprehensive meta-analysis demonstrates that patients with papillary thyroid microcarcinoma managed via active surveillance experience significantly better health-related quality of life and fewer treatment-related symptoms than those undergoing surgery, reinforcing the case for de-escalation in low-risk cases.

news Oncology Urology

Metformin Fails to Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obese Men

By MedXY 11/23/2025

The MAST phase III trial found no benefit of metformin (850 mg twice daily) versus placebo for delaying progression in men with low‑risk prostate cancer on active surveillance; a prespecified subgroup showed increased pathologic progression in obese patients.

news Oncology Urology

Metformin Does Not Delay Progression on Active Surveillance for Low‑Risk Prostate Cancer — Unexpected Signal in Obesity

By MedXY 11/23/2025

A randomized phase III trial (MAST) found metformin did not prolong progression‑free survival in men on active surveillance for low‑risk prostate cancer; an exploratory subgroup showed increased pathologic progression in obese patients.

Oncology Specialties

Long-Term Durability of Active Surveillance in Small, Low-Risk Papillary Thyroid Cancer: Age-Related Outcomes and Clinical Implications

By MedXY 08/22/2025

Active surveillance is a durable management strategy for small, low-risk papillary thyroid cancer, especially among older adults who show significantly lower crossover rates to surgery.